{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:49:52Z","timestamp":1773661792492,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T00:00:00Z","timestamp":1160697600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>Azidothymidine, a nucleoside\u2010analogue reverse transcriptase inhibitor (NRTI), is a commonly used antiretroviral drug in AIDS treatment, however its use is limited by severe toxic side effects due to its influence on mitochondria that result in myopathy, particularly affecting the cardiac muscle. We suggest that effective protection of azidothymidine\u2010induced cardiopathology can be expected from drugs that are capable of targeting mitochondria. Therefore the present study in mice was carried out with mildronate, a cardioprotective drug of the aza\u2010butyrobetaine class, which previously has been shown to act as a highly potent protector of mitochondrial processes. In our study, saline (control), azidothymidine (50 mg\/kg), mildronate (50, 100 and 200 mg\/kg), and azidothymidine + mildronate (at the doses mentioned) were injected intraperitoneally daily in separate groups of mice for two weeks. At the termination of the experiment, mice were sacrificed, the hearts were removed and cardiac tissue was examined morphologically and immunohistochemically. It was found that azidothymidine, compared to control and mildronate groups, induced major morphologic changes in cardiac tissue, which were manifestated as degeneration and inflammation. These changes were prevented when mildronate was co\u2010administered with azidothymidine. Mildronate also reduced the azidothymidine\u2010induced expression of nuclear factor \u03baBp65 (NF\u2010\u03baBp65). The obtained data demonstrate a high ability of mildronate of preventing azidothymidine\u2010induced cardiopathologic changes, and suggest mildronate's indirect action on azidothymidine\u2010caused oxidative stress reactions leading to mitochondrial dysfunction. This offers a rational combination of mildronate with azidothymidine or other anti\u2010HIV drugs for beneficial application in AIDS therapy.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2006.pto_543.x","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T01:04:51Z","timestamp":1160787891000},"page":"323-328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Protection of Azidothymidine\u2010Induced Cardiopathology in Mice by Mildronate, a Mitochondria\u2010Targeted Drug"],"prefix":"10.1111","volume":"99","author":[{"given":"Vija","family":"Klusa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Pupure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergejs","family":"Isajevs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juris","family":"Rumaks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Gordjushina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Kratovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immanuels","family":"Taivans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simons","family":"Svirskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Viksna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivars","family":"Kalvinsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1997.tb00849.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800568"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00125-1"},{"key":"e_1_2_6_5_1","first-page":"CD003510","article-title":"Antiretrovirals for reducing the risk of mother\u2010to\u2010child transmission of HIV infection","volume":"2","author":"Brocklehurst P.","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_6_1","first-page":"311","article-title":"Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle","volume":"38","author":"Corcuera Pindado M. T.","year":"1994","journal-title":"Eur. J. Histochem."},{"key":"e_1_2_6_7_1","first-page":"155","article-title":"Mildronate: cardioprotective action through carnitine\u2010lowering effect","volume":"9","author":"Dambrova M.","year":"2002","journal-title":"Trends Cardiovasc. Med."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.06.020"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00272002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70275-X"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00723-X"},{"key":"e_1_2_6_12_1","first-page":"157","article-title":"Effect of 3\u2010(2,2,2,\u2010trimethylhydrazinium)propionate, gamma\u2010butyrobetaine hydroxylase inhibitor, on isoproterenol\u2010induced mitochondrial disfunction","volume":"64","author":"Hanaki Y.","year":"1989","journal-title":"Res. Commun. Chem. Phatol. Pharmacol."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007093926315"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0066-782X2003000300007"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-3565(24)29674-9","article-title":"A novel zidovudine uptake system in microglia","volume":"176","author":"Hong M.","year":"2001","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.2001.00842.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2004.06.015"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1998.0757"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/dna.1996.15.363"},{"key":"e_1_2_6_20_1","first-page":"5","article-title":"Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS","volume":"86","author":"Peters B. S.","year":"1993","journal-title":"Quart. J. Med."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001774507"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.016003534.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000211732.76668.d2"},{"key":"e_1_2_6_24_1","first-page":"13","article-title":"[Mildronate: mechanisms of action, prospects in the correction of pathologic states]","volume":"29","author":"Shutenko Zh. B.","year":"1995","journal-title":"Khimiko-Farmacevticheskij Zhurnal"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(98)00199-3"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01377-8"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00256.2001"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.84.9.1095"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2006.pto_543.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2006.pto_543.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T13:33:53Z","timestamp":1736602433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2006.pto_543.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1742-7843.2006.pto_543.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_543.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"2006-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}